A Phase III Study of NK105 in Patients With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Nos Metastatic Recurrent
Interventions: DRUG: NK105|DRUG: Paclitaxel
Sponsor: Nippon Kayaku Co., Ltd.